Nov 15, 2013 Issue
AAP Releases Guideline on Managing Type 2 Diabetes Mellitus in Patients 10 to 18 Years of Age [Practice Guidelines]

Childhood type 2 diabetes poses a challenge to many physicians who are not used to treating this disease in such young patients. The American Academy of Pediatrics (AAP) has released a guideline of evidence-based recommendations for treating type 2 diabetes in patients 10 to 18 years of age. The gui...

Sep 1, 2013 Issue
Aliskiren Worsens Outcomes in High-Risk Patients with Diabetes [POEMs]

Aliskiren increases the likelihood of adverse cardiovascular outcomes in patients with diabetes and kidney or heart disease, and cannot be recommended.

Aug 1, 2013 Issue
Diabetic Foot Infections [Article]

Diabetic foot infection, defined as soft tissue or bone infection below the malleoli, is the most common complication of diabetes mellitus leading to hospitalization and the most frequent cause of nontraumatic lower extremity amputation. Diabetic foot infections are diagnosed clinically based on the...

May 15, 2013 Issue
Bromocriptine Mesylate (Cycloset) for Type 2 Diabetes Mellitus [STEPS]

Cycloset will lower A1C levels by 0.3 to 0.5 percent when taken alone or in combination with a sulfonylurea, without undesirable adverse effects such as hypoglycemia and weight gain. It will not cause further improvement of glucose control when used with insulin, metformin, or other hypoglycemic age...

Apr 15, 2013 Issue
Metformin Use in Adolescents [FPIN's Clinical Inquiries]

There are no studies evaluating whether metformin prevents or delays the onset of diabetes in adolescents who are obese. In adults, metformin is as effective as lifestyle interventions in preventing increases in A1C and fasting glucose levels, but it is less effective in preventing or delaying the o...

Apr 15, 2013 Issue
Diabetes: Treating Hypertension [Clinical Evidence Handbook]

What are the effects of antihypertensives and different blood pressure targets in persons with diabetes and hypertension?

Apr 1, 2013 Issue
Screening for Type 2 Diabetes Mellitus: 10-Year Mortality Not Improved [POEMs]

Screening high-risk patients for diabetes provides no 10-year mortality benefit.

Mar 1, 2013 Issue
Diabetic Ketoacidosis: Evaluation and Treatment [Article]

Diabetic ketoacidosis is characterized by a serum glucose level greater than 250 mg per dL, a pH less than 7.3, a serum bicarbonate level less than 18 mEq per L, an elevated serum ketone level, and dehydration. Insulin deficiency is the main precipitating factor. Diabetic ketoacidosis can occur in p...

Jan 15, 2013 Issue
ACP Updates Guideline on Oral Pharmacologic Treatments for Type 2 Diabetes Mellitus [Practice Guidelines]

The American College of Physicians (ACP) has published an updated guideline on the oral pharmacologic management of type 2 diabetes. Recommendations are based on a systematic evidence review of head-to-head comparisons of oral pharmacologic treatments for type 2 diabetes, and an evidence report spon...

Dec 15, 2012 Issue
Linagliptin (Tradjenta) for the Treatment of Diabetes Mellitus [STEPS]

Linagliptin reduces A1C levels to a lesser extent than first-line therapy (metformin) and is significantly more expensive than metformin and sulfonylureas. Importantly, its ability to affect diabetes-related morbidity and mortality is not known.

Pages: Previous 1 2 3 4 5 6 7 8 9 10 11 ... 17 Next

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now